![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PRO-ETHIC'S MIGRAINE DRUG MOVES TO PHASE III TRIAL
PRO-ETHIC'S MIGRAINE DRUG MOVES TO PHASE III TRIAL
May 23, 2006
Pro-Ethic Pharmaceuticals has initiated its pivotal Phase III trial of its migraine product candidate, PRO-513. The study will involve 650 patients in 21 centers over the next eight months.
ProEthic obtained the exclusive U.S. and Canadian marketing rights for PRO-513 from a Swiss drug development company in 2005. The company expects the drug to go to market in early 2008.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct